Key Takeaways
- • Digital health venture funding reached $7.4 billion in the first half of 2026, marking the strongest H1 performance since the pandemic peak, with a $1 billion increase compared to H1 2025 ($6.4 billion) and average deal size climbing 46% year-over-year to $29.6 million.
- • Healthcare now captures nearly half of all vertical AI spending, with AI drug discovery projected to hit $1.5 billion in 2025—more than tripling from $450 million in 2024—reflecting a structural shift toward computational therapeutics and predictive modeling.
- • M&A activity surged 47% this quarter with 56 deals closed, signaling investor preference for commercial adoption over regulatory clearance alone; Abbott's $23 billion acquisition of Exact Sciences represents the quarter's largest deal, leveraging proven market traction of the Cologuard screening model.
- • A critical adoption gap persists: less than 20% of enterprise healthcare data is AI-ready without substantial preparation, as legacy EHR and CRM systems were built for billing and compliance rather than predictive analytics, creating inconsistent data structures across the industry.
- • Commercial footprint and proven revenue generation now determine valuation premiums; DeepHealth paid $269 million for Gleamer based on 700+ hospital contracts, while Oxipit's world-first autonomous AI certification yielded limited acquisition value due to negligible 2024 revenue of $27.6 thousand.
Summary
Digital health venture funding surged to $7.4 billion across the first half of 2026, establishing a decisive recovery trajectory and marking the strongest H1 period since the pandemic peak. This represents a $1 billion increase from H1 2025's $6.4 billion, with 244 deals closed and average deal size reaching $29.6 million—a 46% year-over-year increase. The funding momentum reflects institutional investor confidence in digital health's structural tailwinds, particularly around AI-driven applications in drug discovery and clinical workflows.
Artificial intelligence emerged as the dominant funding driver, with healthcare now capturing nearly half of all vertical AI investment. AI spending in healthcare is projected to reach $1.5 billion in 2025, more than tripling from $450 million the prior year, according to the CB Insights State of Digital Health Q1'26 report. This concentration reflects a strategic reorientation toward computational drug discovery, diagnostic optimization, and predictive analytics rather than administrative automation.
Despite robust capital deployment, a critical operational gap constrains value realization. Less than 20% of enterprise healthcare data is currently AI-ready without substantial preparation, creating a readiness deficit that undermines deployment velocity. Most healthcare data systems—including electronic health records and customer relationship management platforms—were originally architected for billing, compliance, and sales tracking rather than predictive modeling. This legacy architecture produces inconsistent data structures, such as mixed temperature units and non-standardized free-text diagnosis codes, requiring extensive preprocessing before algorithmic applications.
M&A activity accelerated sharply, with 56 transactions completed in the quarter reflecting a 47% sequential increase. The market now explicitly prioritizes commercial adoption and revenue traction over regulatory clearance alone. Abbott's $23 billion acquisition of Exact Sciences, the quarter's largest deal, exemplifies this thesis—the deal capitalized on Cologuard's established market position and screening model scalability. Similarly, DeepHealth's $269 million acquisition of Gleamer was justified by an existing footprint of 700+ hospital contracts, demonstrating that installed bases and customer adhesion now command substantial acquisition premiums. Conversely, Oxipit—despite holding world-first autonomous AI certification—attracted limited valuation interest due to negligible 2024 revenue of $27.6 thousand, underscoring that regulatory credentials alone no longer justify valuations absent demonstrated commercial traction.
Artificial intelligence emerged as the dominant funding driver, with healthcare now capturing nearly half of all vertical AI investment. AI spending in healthcare is projected to reach $1.5 billion in 2025, more than tripling from $450 million the prior year, according to the CB Insights State of Digital Health Q1'26 report. This concentration reflects a strategic reorientation toward computational drug discovery, diagnostic optimization, and predictive analytics rather than administrative automation.
Despite robust capital deployment, a critical operational gap constrains value realization. Less than 20% of enterprise healthcare data is currently AI-ready without substantial preparation, creating a readiness deficit that undermines deployment velocity. Most healthcare data systems—including electronic health records and customer relationship management platforms—were originally architected for billing, compliance, and sales tracking rather than predictive modeling. This legacy architecture produces inconsistent data structures, such as mixed temperature units and non-standardized free-text diagnosis codes, requiring extensive preprocessing before algorithmic applications.
M&A activity accelerated sharply, with 56 transactions completed in the quarter reflecting a 47% sequential increase. The market now explicitly prioritizes commercial adoption and revenue traction over regulatory clearance alone. Abbott's $23 billion acquisition of Exact Sciences, the quarter's largest deal, exemplifies this thesis—the deal capitalized on Cologuard's established market position and screening model scalability. Similarly, DeepHealth's $269 million acquisition of Gleamer was justified by an existing footprint of 700+ hospital contracts, demonstrating that installed bases and customer adhesion now command substantial acquisition premiums. Conversely, Oxipit—despite holding world-first autonomous AI certification—attracted limited valuation interest due to negligible 2024 revenue of $27.6 thousand, underscoring that regulatory credentials alone no longer justify valuations absent demonstrated commercial traction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.